Company Directory - Centre for Cellular and Molecular Platforms
Company Details - Centre for Cellular and Molecular Platforms
Centre for Cellular and Molecular Platforms
WebsiteC-CAMP is a deep-science innovation hub that focuses on enhancing healthcare through innovative technologies.
CCI Score
CCI Score: Centre for Cellular and Molecular Platforms
58.74
-0.01%
Latest Event
Partnership with Tamil Nadu Government Bolsters Public Health
C-CAMP has partnered with the Government of Tamil Nadu to strengthen the state's public health system through indigenous health technologies and CSR collaborations, including initiatives such as solar-powered vaccine storage and remote monitoring for disease management.
Take Action
So what can you do? Support C-CAMP by shopping, spreading the word, or offering your support.
- Shop Alternatives
SEE ALL - Use Your Voice
OTHER TOOLS - Investigate
- Share the Score
SUPPORT CCI
LEADER
Centre for Cellular and Molecular Platforms is currently rated as a Leader.
Latest Events
- MAY302025
C-CAMP has partnered with the Government of Tamil Nadu to strengthen the state's public health system through indigenous health technologies and CSR collaborations, including initiatives such as solar-powered vaccine storage and remote monitoring for disease management.
- AUG012024
The Centre for Cellular and Molecular Platforms (C-CAMP) has announced a strategic partnership with the UK Department of Health and Social Care’s Global AMR Innovation Fund to nurture and fund innovations addressing antimicrobial resistance in the environment, with a focus on supporting low- and middle-income countries.
+60
Public and Political Behavior
May 30
Collaborating with a government department to address a critical public health challenge reinforces democratic, public-oriented policies and demonstrates a commitment to collective well-being against threats like AMR, which can disproportionately affect vulnerable populations.
+70
Business Practices and Ethical Responsibility
May 30
The initiative supports ethical business practices by mobilizing resources and expertise to develop innovative solutions for combating AMR, thereby benefiting public health, particularly in vulnerable low- and middle-income regions.
+75
Technology and Services Impact
May 30
By leveraging its role as a deep-science innovation hub, C-CAMP is enhancing its technological impact to develop advanced solutions addressing AMR. This strengthens not just healthcare innovation, but also supports progressive public health goals globally.
- JUL242024
On July 24, 2024, C-CAMP announced a partnership with the UK Department of Health and Social Care's Global AMR Innovation Fund. The initiative commits approximately £5.1 million over three years to support 15-20 startups addressing antimicrobial resistance challenges through innovative healthcare technologies and mentorship.
+50
Business Practices and Ethical Responsibility
May 30
C-CAMP's collaboration with the Global AMR Innovation Fund represents a forward-thinking business practice that emphasizes ethical responsibility and social impact. By supporting startups addressing antimicrobial resistance, the company demonstrates a commitment to public health and innovation, aligning with progressive values.
+40
Technology and Services Impact
May 30
The initiative's focus on providing technological and financial backing to startups targeting antimicrobial resistance highlights a positive impact within the technology and services sector. This move underlines C-CAMP's role in fostering innovative healthcare solutions that benefit society.
- JUL172024
C-CAMP signed a Memorandum of Understanding with the MS Swaminathan Research Foundation to launch the Rural Agriculture INnovation (RAIN) program, aiming to drive deep science innovation and technology adoption in India’s food, agriculture, and allied sectors. The initiative targets sustainable practices and supports small and marginal farmers through improved agritech solutions.
+70
Business Practices and Ethical Responsibility
May 30
The MoU underscores C-CAMP's commitment to business practices that foster ethical responsibility and community support. By promoting innovation in agriculture and facilitating technology adoption among local farmer groups, the initiative contributes positively to sustainable development and worker empowerment in rural areas.
+70
Technology and Services Impact
May 30
The collaboration is set to enhance the technology and services in the agricultural sector, driving forward deep science innovation through agritech products. This move is poised to benefit local communities by integrating advanced technological solutions into sustainable farming practices.
- FEB022023
On February 2, 2023, C-CAMP launched the National Diagnostics Catapult in New Delhi to scale up India’s molecular diagnostics capacity. The initiative, supported by the Bangalore Life Sciences Cluster and funded by The Rockefeller Foundation, Bill & Melinda Gates Foundation, and FIND, aims to enhance preparedness for current and future pandemics by building affordable and accessible diagnostics infrastructure.
+80
Business Practices and Ethical Responsibility
May 30
The launch of the National Diagnostics Catapult demonstrates strong ethical responsibility by expanding access to affordable, high-quality diagnostics. This initiative enhances public health outcomes and supports inclusive innovation, aligning with progressive action and community well-being.
+70
Economic and Structural Influence
May 30
By establishing the National Diagnostics Catapult, C-CAMP is contributing to long-term structural improvements in the nation’s healthcare infrastructure. This economic and structural influence promotes sustainable growth and enhances public readiness for outbreaks, reflecting progressive, anti-authoritarian public service.
- FEB022023
C-CAMP launched the InDx 2.0 National Diagnostics Catapult on February 2, 2023 to boost India's preparedness for pandemics by scaling up diagnostics for infectious diseases, building on the earlier successful COVID-19 diagnostics platform.
+75
Technology and Services Impact
May 30
The launch of the National Diagnostics Catapult represents a significant technological initiative that enhances public health preparedness and surveillance capabilities. This innovation helps empower communities and promotes self-reliance in diagnostics, aligning with anti-authoritarian and progressive values by prioritizing public welfare over profit-driven motives.
- FEB012023
Centre for Cellular and Molecular Platforms (C-CAMP) launched the C-CAMP InDx 2.0 programme aimed at scaling up diagnostics capacity, boosting pandemic preparedness, and building a robust surveillance platform. The initiative, supported by government agencies and global foundations including the Rockefeller Foundation, Bill and Melinda Gates Foundation, and FIND, seeks to enhance affordable and high-quality diagnostic solutions.
+80
Technology and Services Impact
May 30
C-CAMP InDx 2.0 represents a significant technological and service impact by expanding access to affordable diagnostics, which aligns with progressive public health initiatives and aids in the battle against authoritarian neglect in healthcare. This proactive innovation supports equitable health outcomes and builds capacity in lower- and middle-income countries.
Centre for Cellular and Molecular Platforms launches programme to boost pandemic preparedness
+70
Public and Political Behavior
May 30
The programme is backed by collaborations with government agencies and influential global philanthropic organizations, demonstrating responsible public engagement and enhancing societal resilience against crises, which is a core aspect of progressive public and political behavior.
Centre for Cellular and Molecular Platforms launches programme to boost pandemic preparedness
Alternatives
Belgium (Ghent), Belgium
78.10
Raleigh, USA
55.85
Zug, Switzerland
22.68
Somerset, United States
1.17
Cambridge, United States
-12.92
Cranbury, United States
-14.96
Basel, Switzerland
-19.51
Seattle, United States
-37.70
Menlo Park, United States
-49.21
Corporation
26.91
Industries
- 541714
- Research and Development in Biotechnology (except Nanobiotechnology)
- 621511
- Medical Laboratories
- 541711
- Research and Development in Biotechnology